https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-q2-2026-results-clinical-trial-progress BiopharmaWatch en 2026-07-31T21:34:00.000Z FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate https://www.biopharmawatch.com/news/PFSA/profusa-signs-option-agreement-acquire-g3-vision-labs BiopharmaWatch en 2026-07-31T21:15:00.000Z Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs https://www.biopharmawatch.com/news/XRTX/xortx-announces-director-resignation BiopharmaWatch en 2026-07-31T21:00:00.000Z XORTX Announces Director Resignation https://www.biopharmawatch.com/news/ENTX/entera-bio-participate-canaccord-growth-conference BiopharmaWatch en 2026-07-31T20:30:00.000Z Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PRPO/precipio-q2-2026-shareholder-update-call BiopharmaWatch en 2026-07-31T20:00:00.000Z Precipio Announces Q2-2026 Shareholder Update Call https://www.biopharmawatch.com/news/PCVX/aviator-game-download-risk-management BiopharmaWatch en 2026-07-31T19:37:50.000Z Potential_rewards_await_with_aviator_game_download_and_careful_risk_management_t https://www.biopharmawatch.com/news/PCVX/covid-19-coronavirus-disease-2019 BiopharmaWatch en 2026-07-31T19:25:47.000Z Coronavirus disease 2019 https://www.biopharmawatch.com/news/IMRX/aja-harbert-joins-immuneering BiopharmaWatch en 2026-07-31T16:21:41.000Z Aja Harbert https://www.biopharmawatch.com/news/PCVX/stoiximan-new-platform-launch BiopharmaWatch en 2026-07-31T15:42:40.000Z Εύκολη_πρόσβαση_στη_στοιχηματική_πλατφόρμα https://www.biopharmawatch.com/news/IMRX/paris-offor-joins-immuneering BiopharmaWatch en 2026-07-31T15:36:28.000Z Paris Offor https://www.biopharmawatch.com/news/PCVX/considerable-progress-in-competitive-gaming BiopharmaWatch en 2026-07-31T14:52:07.000Z Considerable_progress_from_initial_steps_to_advanced_play_with_https_vegasheros- https://www.biopharmawatch.com/news/PCVX/automaty-z-magnesami-niespodzianki-i-wygrane BiopharmaWatch en 2026-07-31T14:50:57.000Z Automaty_z_magnesami_czyli_niespodzianki_i_wygrane_na_https_the-magnetic-slots_n https://www.biopharmawatch.com/news/PCVX/atmosphaere-kreieren-zuhause-neu-denken-thegolisimo BiopharmaWatch en 2026-07-31T14:47:35.000Z Atmosphäre_kreieren_und_das_Zuhause_neu_denken_mit_thegolisimo_at_für_individu https://www.biopharmawatch.com/news/MBRX/moleculin-announces-pricing-public-offering BiopharmaWatch en 2026-07-31T14:12:00.000Z Moleculin Announces Pricing of $9.3 Million Public Offering https://www.biopharmawatch.com/news/NCEL/newcelx-announces-1-4-million-financing-premium-pricing BiopharmaWatch en 2026-07-31T13:00:00.000Z NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing https://www.biopharmawatch.com/news/SDEV/stablecoin-development-corporation-q2-2026-results BiopharmaWatch en 2026-07-31T12:30:00.000Z Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NMAD/nomad-options-trading-begins-cboe BiopharmaWatch en 2026-07-31T12:30:00.000Z NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange https://www.biopharmawatch.com/news/OGN/organon-announces-quarterly-dividend BiopharmaWatch en 2026-07-31T12:30:00.000Z Organon Announces Quarterly Dividend https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-august-2026 BiopharmaWatch en 2026-07-31T12:30:00.000Z PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026 https://www.biopharmawatch.com/news/RDGT/ridgetech-fiscal-year-2026-financial-results BiopharmaWatch en 2026-07-31T12:30:00.000Z Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-quantum-platform-clinical-data-analytics BiopharmaWatch en 2026-07-31T12:20:00.000Z SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-q2-2026-financial-results BiopharmaWatch en 2026-07-31T12:15:00.000Z IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-positive-data-venetoclax-failure BiopharmaWatch en 2026-07-31T12:10:18.000Z Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients https://www.biopharmawatch.com/news/GCTK/lokahi-therapeutics-ai2-futures-lab-expansion BiopharmaWatch en 2026-07-31T12:00:00.000Z Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline https://www.biopharmawatch.com/news/ELUT/elutia-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-31T12:00:00.000Z Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/PMI/picard-medical-emperor-total-artificial-heart-architecture BiopharmaWatch en 2026-07-31T12:00:00.000Z Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026 https://www.biopharmawatch.com/news/ABBV/abbvie-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-31T11:47:00.000Z AbbVie Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ELAN/elanco-2025-impact-report-animal-health-innovation BiopharmaWatch en 2026-07-31T11:32:00.000Z Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs https://www.biopharmawatch.com/news/MDCX/medicus-pharma-uae-authorization-teverelix-endometriosis-study BiopharmaWatch en 2026-07-31T11:30:00.000Z Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis https://www.biopharmawatch.com/news/NVO/novo-nordisk-zeus-phase-3-trial-update BiopharmaWatch en 2026-07-31T11:21:00.000Z Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation https://www.biopharmawatch.com/news/INMB/inmune-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-07-31T11:15:58.805Z INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th https://www.biopharmawatch.com/news/OCGN/ocugen-participate-august-investor-conferences BiopharmaWatch en 2026-07-31T11:15:21.037Z Ocugen to Participate in Upcoming August Investor Conferences https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-31T11:13:15.202Z Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-31T11:12:24.597Z Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-31T11:01:00.000Z Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/TLSA/tiziana-reports-reduction-brain-inflammation-msatreatment BiopharmaWatch en 2026-07-31T11:00:00.000Z Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab https://www.biopharmawatch.com/news/INMB/inmune-bio-receives-rd-rebates-4-6-million BiopharmaWatch en 2026-07-31T11:00:00.000Z INmune Bio Receives R&D Rebates of Approximately $4.6 Million https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-business-update BiopharmaWatch en 2026-07-31T11:00:00.000Z Radiopharm Theranostics Reports Business Update https://www.biopharmawatch.com/news/BTSG/brightspring-health-q2-2026-financial-results BiopharmaWatch en 2026-07-31T10:00:00.000Z BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance https://www.biopharmawatch.com/news/TLX/telix-h1-2026-results-investor-webcast-notification BiopharmaWatch en 2026-07-30T22:37:00.000Z Telix H1 2026 Results: Investor Webcast Notification https://www.biopharmawatch.com/news/REPL/replimune-fda-advisory-committee-rp1-advanced-melanoma BiopharmaWatch en 2026-07-30T22:15:00.000Z Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-participate-canaccord-conference BiopharmaWatch en 2026-07-30T21:57:00.000Z Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/DBVT/dbv-technologies-sale-50-million-ads-atm-program BiopharmaWatch en 2026-07-30T21:40:00.000Z DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-69-per-share BiopharmaWatch en 2026-07-30T20:30:00.000Z STERIS Raises Dividend to $0.69 per share https://www.biopharmawatch.com/news/CLLS/cellectis-second-quarter-financial-results-2026 BiopharmaWatch en 2026-07-30T20:30:00.000Z Cellectis to Report Second Quarter Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-third-quarter-2026 BiopharmaWatch en 2026-07-30T20:15:00.000Z CooperCompanies Announces Release Date for Third Quarter 2026 https://www.biopharmawatch.com/news/ENTA/sars-cov-2-resistance-pathways-edp-235 BiopharmaWatch en 2026-07-30T20:05:16.000Z SARS-CoV-2 Resistance Pathways to EDP-235 https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-q2-2026-results-clinical-milestones BiopharmaWatch en 2026-07-30T20:05:00.000Z Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-canaccord-growth-conference-2023 BiopharmaWatch en 2026-07-30T20:05:00.000Z Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q2-2026-results-conference-call BiopharmaWatch en 2026-07-30T20:05:00.000Z Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026 https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-q2-2026-investor-update-call BiopharmaWatch en 2026-07-30T20:05:00.000Z Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call https://www.biopharmawatch.com/news/PRTA/prothena-report-q2-2026-results-august-6 BiopharmaWatch en 2026-07-30T20:05:00.000Z Prothena to Report Second Quarter 2026 Financial Results on August 6 https://www.biopharmawatch.com/news/GH/guardant-health-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/FLGT/fulgent-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Fulgent Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ILMN/illumina-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q2-2026-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Castle Biosciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/PEN/penumbra-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Penumbra, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CV/capsovision-second-quarter-2026-results-release BiopharmaWatch en 2026-07-30T20:05:00.000Z CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ABVX/abivax-positive-pre-nda-interaction-fda-obefazimod BiopharmaWatch en 2026-07-30T20:05:00.000Z Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T20:05:00.000Z Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 https://www.biopharmawatch.com/news/SYK/stryker-second-quarter-2026-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Stryker reports second quarter 2026 operating results https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability https://www.biopharmawatch.com/news/DXCM/dexcom-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:02:00.000Z Dexcom Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CERS/cerus-corporation-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Cerus Corporation Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-30T20:01:00.000Z Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/CDNA/caredx-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z CareDx Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-third-quarter-dividend BiopharmaWatch en 2026-07-30T20:01:00.000Z AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND https://www.biopharmawatch.com/news/GRAL/grail-presentation-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-30T20:01:00.000Z GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-corporate-update-q2-2026-results BiopharmaWatch en 2026-07-30T20:01:00.000Z PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-kathleen-kennedy-svp-sales-marketing BiopharmaWatch en 2026-07-30T20:01:00.000Z InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing https://www.biopharmawatch.com/news/ANNX/annexon-secures-credit-facility-200-million BiopharmaWatch en 2026-07-30T20:01:00.000Z Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q2-2026-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q2-2026 BiopharmaWatch en 2026-07-30T20:01:00.000Z Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/KROS/keros-therapeutics-milestone-payment-takeda BiopharmaWatch en 2026-07-30T20:01:00.000Z Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/XENE/xenon-report-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Xenon to Report Q2 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/MDXH/mdxhealth-q2-2026-financial-results-release BiopharmaWatch en 2026-07-30T20:00:00.000Z Mdxhealth to Release Second Quarter 2026 Financial Results on August 13 https://www.biopharmawatch.com/news/IVA/inventiva-preliminary-financial-results-h1-2026 BiopharmaWatch en 2026-07-30T20:00:00.000Z Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹ https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-private-placement-nasdaq BiopharmaWatch en 2026-07-30T18:23:00.000Z 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/SRXH/srx-global-acquires-shares-jersey-mikes-ipo BiopharmaWatch en 2026-07-30T18:04:00.000Z SRX Global Acquires Shares in Jersey Mike’s $1 Billion Initial Public Offering https://www.biopharmawatch.com/news/AMGN/repatha-cmuh-favorable-opinion-cardiovascular-risk BiopharmaWatch en 2026-07-30T16:45:00.000Z AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC https://www.biopharmawatch.com/news/ELV/elevance-health-connected-cancer-care-model BiopharmaWatch en 2026-07-30T16:00:00.000Z Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey https://www.biopharmawatch.com/news/LEXX/lexaria-reverse-stock-split-effective-date BiopharmaWatch en 2026-07-30T15:02:41.000Z Lexaria Announces Effective Date for Reverse Stock Split https://www.biopharmawatch.com/news/SNY/sanofi-semi-annual-financial-report-2026 BiopharmaWatch en 2026-07-30T13:38:00.000Z Communiqué de presse : Rapport financier semestriel 2026 de Sanofi https://www.biopharmawatch.com/news/SNY/sanofi-half-year-financial-report-2026 BiopharmaWatch en 2026-07-30T13:38:00.000Z Press Release: Sanofi’s half-year financial report for 2026 https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-deramiocel-fda-update BiopharmaWatch en 2026-07-30T13:30:00.000Z Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel https://www.biopharmawatch.com/news/HNGE/hinge-health-lowers-fall-risk-adults-65 BiopharmaWatch en 2026-07-30T13:05:00.000Z Study finds Hinge Health significantly lowers fall risk for adults aged 65+ https://www.biopharmawatch.com/news/CODX/co-diagnostics-q2-2026-earnings-release-webcast BiopharmaWatch en 2026-07-30T13:00:00.000Z Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/BMRN/biomarin-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-30T13:00:00.000Z BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET https://www.biopharmawatch.com/news/CVS/cvs-health-wins-us-customer-experience-awards-2026 BiopharmaWatch en 2026-07-30T13:00:00.000Z CVS Health® named Overall Winner and wins four gold awards at 2026 US Customer Experience Awards https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovation-3-trial-update BiopharmaWatch en 2026-07-30T13:00:00.000Z IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer https://www.biopharmawatch.com/news/CVM/cel-sci-multikine-phase-3-data-publication BiopharmaWatch en 2026-07-30T12:31:00.000Z Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients https://www.biopharmawatch.com/news/AIDX/20-20-biolabs-investor-webinar-east-asia-strategy BiopharmaWatch en 2026-07-30T12:31:00.000Z 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour https://www.biopharmawatch.com/news/AMGN/amgen-repatha-chmp-opinion-broader-use BiopharmaWatch en 2026-07-30T12:30:00.000Z LA OPINIÓN FAVORABLE DEL CHMP RESPALDA UN USO MÁS AMPLIO DE REPATHA® DE AMGEN https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-q2-2026-business-update BiopharmaWatch en 2026-07-30T12:30:00.000Z Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 https://www.biopharmawatch.com/news/VERU/veru-fireside-chat-canaccord-growth-conference BiopharmaWatch en 2026-07-30T12:30:00.000Z Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference https://www.biopharmawatch.com/news/CMND/clearmind-positive-safety-findings-cmnd-100-trial BiopharmaWatch en 2026-07-30T12:30:00.000Z Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial https://www.biopharmawatch.com/news/IRON/disc-medicine-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T12:30:00.000Z Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CING/cingulate-phase-3-adhd-trial-results-publication BiopharmaWatch en 2026-07-30T12:30:00.000Z Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology https://www.biopharmawatch.com/news/LITS/lite-strategy-repurchases-shares-increasing-litecoin-backing BiopharmaWatch en 2026-07-30T12:30:00.000Z Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q2-2026-results-release BiopharmaWatch en 2026-07-30T12:30:00.000Z Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/RKTO/rocket-one-nasa-agreement-space-ai-technology BiopharmaWatch en 2026-07-30T12:19:00.000Z Rocket One and NASA Reach Agreement to Advance Space AI Technology https://www.biopharmawatch.com/news/VNRX/volition-advances-nuq-nets-platform-commercialization BiopharmaWatch en 2026-07-30T12:17:00.000Z Volition Advances Nu.Q® NETs Platform Towards Commercialization https://www.biopharmawatch.com/news/HYPR/hyperfine-peer-reviewed-publications-swoop-system BiopharmaWatch en 2026-07-30T12:15:00.000Z Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care https://www.biopharmawatch.com/news/AMGN/repatha-chmp-positive-opinion-amgen BiopharmaWatch en 2026-07-30T12:15:00.000Z POZYTYWNA OPINIA CHMP OTWIERA DROGĘ DO SZERSZEGO STOSOWANIA LEKU REPATHA® FIRMY AMGEN PRZED WYSTĄPIENIEM PIERWSZEGO ZAWAŁU SERCA LUB UDARU MÓZGU https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-acesot-1051-update BiopharmaWatch en 2026-07-30T12:09:46.921Z Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 https://www.biopharmawatch.com/news/SVRA/savara-patent-grants-molbreevi-europe-australia BiopharmaWatch en 2026-07-30T12:05:00.000Z Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-q2-financial-results-conference-call BiopharmaWatch en 2026-07-30T12:05:00.000Z Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/ABBV/juvederm-day-returns-us-august-19 BiopharmaWatch en 2026-07-30T12:00:00.000Z JUVÉDERM® Day Returns to U.S. on August 19 https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q2-2026-report BiopharmaWatch en 2026-07-30T12:00:00.000Z Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 https://www.biopharmawatch.com/news/NTRA/natera-second-quarter-results-august-2026 BiopharmaWatch en 2026-07-30T12:00:00.000Z Natera to Report its Second Quarter Results on August 6, 2026 https://www.biopharmawatch.com/news/CRIS/curis-doses-first-five-patients-takeaim-cll-study BiopharmaWatch en 2026-07-30T12:00:00.000Z Curis Doses First Five Patients in TakeAim CLL Study https://www.biopharmawatch.com/news/ECOR/electrocore-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-update-rain-volume-growth BiopharmaWatch en 2026-07-30T12:00:00.000Z Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T12:00:00.000Z Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-mira-55-skny-1-ind-studies BiopharmaWatch en 2026-07-30T12:00:00.000Z MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T12:00:00.000Z Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q4-fy26 BiopharmaWatch en 2026-07-30T12:00:00.000Z Immutep Quarterly Activities Report Q4 FY26 https://www.biopharmawatch.com/news/EVMN/evommune-phase-2b-trial-evo756-migraine-prophylaxis BiopharmaWatch en 2026-07-30T12:00:00.000Z Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-conference-call-august-2026 BiopharmaWatch en 2026-07-30T12:00:00.000Z Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/PETS/petmed-express-report-q1-fiscal-year-2027 BiopharmaWatch en 2026-07-30T12:00:00.000Z PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-second-quarter-2026-results-report BiopharmaWatch en 2026-07-30T12:00:00.000Z PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/VCEL/vericel-reports-q2-2026-results-guidance-share-repurchase BiopharmaWatch en 2026-07-30T11:55:00.000Z Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-q2-2026-results-highlights BiopharmaWatch en 2026-07-30T11:35:00.000Z Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/DGX/bacterial-vaginosis-sti-co-infection-quest-diagnostics BiopharmaWatch en 2026-07-30T11:30:00.000Z Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-fda-workshop-drug-repurposing BiopharmaWatch en 2026-07-30T11:30:00.000Z Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing https://www.biopharmawatch.com/news/IFRX/inflarx-report-q2-2026-results-august-6 BiopharmaWatch en 2026-07-30T11:30:00.000Z InflaRx to Report Second Quarter 2026 Results on August 6, 2026 https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-ulcerative-colitis-tti-109 BiopharmaWatch en 2026-07-30T11:30:00.000Z Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T11:30:00.000Z Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-august-2026 BiopharmaWatch en 2026-07-30T11:30:00.000Z SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q4-fy26-cash-flow-report BiopharmaWatch en 2026-07-30T11:25:00.000Z Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update https://www.biopharmawatch.com/news/BAX/baxter-reports-second-quarter-2026-results BiopharmaWatch en 2026-07-30T11:15:00.000Z Baxter Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/USNA/usana-glow-consumer-study-results BiopharmaWatch en 2026-07-30T11:04:00.000Z New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow https://www.biopharmawatch.com/news/BEAT/heartbeam-second-quarter-2026-results-conference-call BiopharmaWatch en 2026-07-30T11:00:00.000Z HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time https://www.biopharmawatch.com/news/HSIC/henry-schein-leadership-transitions BiopharmaWatch en 2026-07-30T11:00:00.000Z Henry Schein Announces Leadership Transitions https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-q2-2026-results BiopharmaWatch en 2026-07-30T11:00:00.000Z Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NVAX/novavax-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-30T11:00:00.000Z Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/IMCR/immunocore-q2-2026-financial-results-call BiopharmaWatch en 2026-07-30T11:00:00.000Z Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-private-placement-offering BiopharmaWatch en 2026-07-30T11:00:00.000Z Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-30T11:00:00.000Z Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/EYPT/eyepoint-completes-enrollment-phase-3-trials-duravyu-dme BiopharmaWatch en 2026-07-30T11:00:00.000Z EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) https://www.biopharmawatch.com/news/INMB/inmune-bio-scientific-advisory-board-cordstrom-development BiopharmaWatch en 2026-07-30T11:00:00.000Z INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q2-financial-results-2026 BiopharmaWatch en 2026-07-30T10:59:00.000Z Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-07-30T10:59:00.000Z Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LH/labcorp-2026-second-quarter-results-guidance-update BiopharmaWatch en 2026-07-30T10:50:00.000Z Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance https://www.biopharmawatch.com/news/PFE/pfizer-positive-topline-phase-3-results-litfulo-vitiligo BiopharmaWatch en 2026-07-30T10:45:00.000Z Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo https://www.biopharmawatch.com/news/BFLY/butterfly-network-q2-2026-results BiopharmaWatch en 2026-07-30T10:30:00.000Z Butterfly Network Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STVN/liraglutide-combination-products-stevanato-europe BiopharmaWatch en 2026-07-30T10:30:00.000Z Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries https://www.biopharmawatch.com/news/CYTK/cytokinetics-mhra-authorization-aficamten-nice-guidance BiopharmaWatch en 2026-07-30T10:20:00.000Z Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales https://www.biopharmawatch.com/news/TAK/takeda-fy2026-q1-results-launch-preparations-pipeline-progress BiopharmaWatch en 2026-07-30T06:37:00.000Z Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track https://www.biopharmawatch.com/news/CGON/bcan-think-tank-2026-creto-eap-poster-podium BiopharmaWatch en 2026-07-30T06:29:00.000Z BCAN Think Tank 2026 – Creto EAP Poster and Podium https://www.biopharmawatch.com/news/PHAR/pharming-q2-2026-financial-results-guidance-revision BiopharmaWatch en 2026-07-30T05:00:00.000Z Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use https://www.biopharmawatch.com/news/MESO/mesoblast-ryoncil-revenue-growth-expansion BiopharmaWatch en 2026-07-30T00:57:00.000Z Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch https://www.biopharmawatch.com/news/INO/inovio-announces-public-offering-pricing BiopharmaWatch en 2026-07-30T00:53:00.000Z INOVIO Announces Pricing of $20.0 Million Public Offering https://www.biopharmawatch.com/news/JNJ/jnj-fda-priority-review-amivantamab-head-neck-cancer BiopharmaWatch en 2026-07-30T00:00:00.000Z Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental... https://www.biopharmawatch.com/news/AMGN/positive-opinion-chmp-repatha-amgen BiopharmaWatch en 2026-07-30T00:00:00.000Z POZITÍVNE STANOVISKO VÝBORU PRE LIEKY NA HUMÁNNE POUŽITIE PODPORUJE ŠIRŠIE POUŽÍVANIE LIEKU REPATHA® OD SPOLOČNOSTI AMGEN PRED PRVÝM INFARKTOM ALEBO MOZGOVOU PRÍHODOU Amgen (NASDAQ: AMGN) dnes oznámila, že Výbor pre lieky na humánne použitie (CHMP) Európskej agentúry pre lieky (EMA) prijal pozitívne stanovisko k... https://www.biopharmawatch.com/news/AMGN/chmp-positive-opinion-repatha-amgn BiopharmaWatch en 2026-07-30T00:00:00.000Z POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) der...